Anant Murthy

Anant Murthy

Anant Murthy

General Manager Europe - Argenx

Dr. Anant Murthy is currently the Head of Europe for Argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. In this role, he is responsible for establishing and leading the company’s footprint in the broad and diverse European market.  

Prior to Argenx, he was the Vice President and Head of the Mid-Size Market Region at Alnylam Pharmaceuticals, and was also the Head of Pricing, Market Access and Policy.  In these roles, he oversaw the launch of Alnylam’s RNAi portfolio across more than nine countries, and was responsible for securing approvals from payers and governments across Europe and Canada.  Dr. Murthy’s market access leadership secured reimbursement approvals faster than industry averages, helping to accelerate patients’ access to Alnylam’s rare disease portfolio, while enabling the growth of the business.  In addition, he served as the Managing Director of Alnylam Netherlands with responsibility for the company’s substantial and growing investments in Holland. 

Previously, he worked at ARIAD Pharmaceuticals and Incyte Corporation, following Incyte’s acquisition of ARIAD’s European operations.  During his tenure there, Dr. Murthy served in a number of positions of increasing responsibility, including as Regional Vice President & Head of Pricing & Market Access, as Head of Commercial Partnerships, and as General Manager of Switzerland.  Dr. Murthy led all ex-US pricing & access activities for a novel rare disease drug in hematology, securing premium prices and reimbursement faster than competitors.  Additionally, he closed and led several worldwide distribution alliances that together became a top source of net revenues and margin under his leadership, and closed several business development transactions that provided double-digit millions in non-dilutive capital for the company.   

Prior to ARIAD, Dr. Murthy held several executive leadership positions at Celgene Corporation in both Europe and the US, including Executive Director and Global Head of Pricing & Market Access.  He built and led Celgene’s market access capability and secured reimbursement in key markets for Celgene’s blockbuster hematology and oncology portfolio, which grew to $1B in Europe in less than five years from launch. 

Previously, he held commercial leadership positions at Medtronic, a global leader in medical technology.  He was a legislative advisor to a member of the US House of Representatives and served as a strategy and management consultant with Ernst & Young LLP.  On behalf of life sciences companies seeking to grow their businesses outside of the US, Dr. Murthy has directly negotiated with authorities to secure market access for specialty therapeutics in more than 30 countries.    Dr. Murthy earned his PhD from the Johns Hopkins Bloomberg School of Public Health, an MSc from the London School of Economics, and a BA from the University of Rochester.  A native of New York City, he has lived and worked in Europe for nearly 20 years and currently resides in Geneva, Switzerland, with his wife and daughter. 

Flanders.bio Strategic Partners

Flanders.bio Supporting Partners